Identifying optimal psychosocial interventions for patients receiving office-based buprenorphine

This study investigates which psychosocial interventions most effectively complement office-based buprenorphine/naloxone treatment for opioid use disorder (OUD). Funded by a $5.5 million PCORI contract awarded to the Philadelphia College of Osteopathic Medicine (PCOM), the trial addresses a major evidence gap: while medication-assisted treatment (MAT) with buprenorphine has demonstrated promise, optimal adjunctive behavioral strategies remain unclear. The randomized, pragmatic study will enroll 440 patients receiving buprenorphine/naloxone at four federally qualified health centers and assign participants to one of four conditions: medication alone, medication plus cognitive behavioral therapy (CBT), medication plus peer recovery support, or medication with both CBT and peer support.

By testing CBT and peer support both individually and in combination, the project seeks to identify which psychosocial approach—or combination of approaches—yields the best outcomes for different patient subgroups, enabling more personalized, effective treatment plans. Primary outcomes include opioid abstinence and treatment retention, while secondary outcomes capture quality of life and emergency hospitalizations, providing a broad view of clinical and patient-centered impacts. The study’s design emphasizes real-world settings and stakeholder engagement: the proposal underwent a competitive review process that included patients, caregivers, and other healthcare stakeholders alongside scientists, reflecting PCORI’s emphasis on patient-centered, practical research. The trial’s pragmatic nature—embedded in community health centers that serve medically underserved populations—enhances its potential generalizability and relevance to routine clinical practice.

The researchers highlight the role of behavioral strategies in maximizing pharmaceutical benefits, noting that promising medications often require adjunctive psychosocial supports to promote adherence and sustain positive outcomes. The study will thus not only compare interventions but also explore which approaches best suit different types of patients, acknowledging that there is no one-size-fits-all solution to OUD treatment. Outcomes from this research are intended to inform clinicians, patients, and health systems about tailoring care: which patients might do well with medication alone, which benefit from structured CBT, which gain more from peer recovery support, and whether a combined approach offers additive or synergistic advantages. Beyond its direct clinical implications, the project represents an investment in multidisciplinary research and stakeholder-engaged science. Its findings aim to fill a crucial evidence gap in the integration of psychosocial treatments with MAT in community-based settings, with the potential to shape guidelines, inform training, and improve the quality and personalization of care for individuals with opioid addiction. Enrollment was expected to begin in spring 2020, and the study’s progress and results are anticipated to contribute actionable evidence for treating a pressing public health crisis.